289 Cadonilimab, an anti-PD1/CTLA4 bi-specific antibody with Fc effector null backbone

Affiliations

Na Chen: School of Health Economics and Management, Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China
Xiaoping Jin: 6Akeso Biopharma Inc, Zhongshan city, China
Baiyong Li: 6Akeso Biopharma Inc, Zhongshan city, China
Dennis Xia: 6Akeso Biopharma Inc, Zhongshan city, China
Tingting Zhong: 1Akeso Biopharma Co., Ltd., Zhongshan city, China
Zhaoliang Huang: 1Akeso Biopharma Co., Ltd., Zhongshan city, China
Xinghua Pang: 1Akeso Biopharma Co., Ltd., Zhongshan city, China
Xinrong He: 1Akeso Biopharma Inc., Zhongshan, China
Zhongmin Wang: 1Akeso Biopharma Inc., Zhongshan, China
Xu Xia: 1Akeso Biopharma Inc., Zhongshan, China

Abstract

No abstracts available.

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com